Filgotinib in Ulcerative Colitis: Long-term Outcomes and Treatment Positioning.

Authors

He Zhong, Xiao Ma, Yan Jiao

Published in

Journal of visualized experiments : JoVE. Issue 236. Oct 16, 2026. Epub Oct 16, 2026.

Abstract

The therapeutic landscape of ulcerative colitis (UC) has expanded substantially with biologics and small-molecule agents, yet durable disease control, safety, and treatment sequencing remain important challenges. Filgotinib is an oral inhibitor with preferential activity for Janus kinase 1 (JAK1) relative to JAK2, JAK3, and tyrosine kinase 2. The pivotal SELECTION trial established induction and maintenance efficacy, and long-term extension and real-world studies have reported sustained clinical and patient-reported benefits in selected populations. Direct head-to-head trials remain scarce; most comparative evidence derives from network meta-analyses and nonrandomized cohorts that are vulnerable to heterogeneity and channeling bias. Rare adverse outcomes also remain imprecisely estimated. This narrative review integrates pivotal trials, long-term extension data, full peer-reviewed real-world studies, comparative analyses, guidelines, and regulatory information. It emphasizes cautious interpretation of JAK1 preference, clinically relevant risk assessment and monitoring, reproductive considerations, and geographic variation in therapeutic positioning. Filgotinib should be considered one option within individualized treatment sequencing rather than a uniformly preferred therapy.

PMID:
42891591
Bibliographic data and abstract were imported from PubMed on 18 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.